Human body structural material XX type collagen and biosynthesis method thereof
By designing repeat units and DNA recombination technology for specific amino acid sequences, XX type collagen with triple helical structure was prepared, which solved the problem of insufficient collagen absorption performance in the existing technology, achieved efficient cell adhesion activity, and significantly improved Bioactivity of type XX collagen.
Patent Information
- Application Number
- CN202410969568.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-29
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-18
AI Technical Summary
The lack of theoretical guidance for designing short amino acid sequences in the prior art has led to insufficient transdermal absorption performance of recombinant collagen and relatively lack of research on type XX collagen.
Provides a preparation method for XX type collagen and its biosynthetic human structural materials. By designing repeat units containing specific amino acid sequences, collagen with triple helical structure is formed, cell adhesion is promoted, and recombinant human sources are prepared through DNA recombination technology. XX collagen.
Recombinant humanized XX collagen has higher cell adhesion activity, which is twice that of bovine type I collagen, significantly improving its biological activity.
Smart Images

Figure BDA0004953502740000201 
Figure BDA0004953502740000251 
Figure HDA0004953502820000011
Abstract
Description
[0001] This application claims the priority benefit of the Chinese invention patent application with application date: April 29, 2024, application number: 202410532686.2, and invention name: "Human structural material XX type collagen and its biosynthesis method". Technical Field
[0002] The present application relates to the field of proteins or polypeptides, and specifically to collagen, a preparation method and use thereof. Background Art
[0003] Collagen is a type of protein widely distributed in human connective tissues. It is also the most abundant protein in the human body, accounting for 25% to 35% of the total protein. Its main functions are to maintain the extracellular environment, maintain the normal physiological functions of tissues and organs, and repair body damage. Collagen is a natural biological resource with bio-tissue compatibility, cell-supporting elasticity and degradability that other polymer materials cannot match. Therefore, collagen can be widely used in industries such as medicine and cosmetics.
[0004] Natural collagen molecules can form a special superhelical structure, which is a left-handed helix with three amino acid residues as the basic repeating body. These three amino acid residues are usually Gly-XY. Gly is necessary for the formation of hydrogen bonds in collagen. It has no side chains, which makes collagen densely packed and can maintain skin tension and elasticity.
[0005] In recent years, with the widespread application of genetic engineering technology, researchers have created various types of recombinant collagen. For example, recombinant collagen can be constructed by selecting short amino acid sequences from natural human collagen. The recombinant collagen constructed in this way has advantages such as low immunogenicity, high biological activity, and good stability. In theory, the shorter the amino acid sequence of this recombinant collagen, the better the transdermal absorption performance, but the shorter the amino acid sequence is, the better. How to design a short amino acid sequence so that the constructed recombinant collagen has better transdermal absorption performance, there is no theory in the prior art that can serve as a guide.
[0006] Type XX collagen (COL20) is an unexplored collagen. According to its structural characteristics, type XX collagen is part of the fibril-associated collagen with interrupted triple helix (FACIT) family. COL20A1 RNA expression is enriched in the human brain, and RNA expression in testis and spleen tissues is slightly increased. At present, research on type XX collagen is relatively lacking, and type XX collagen and its preparation method are needed in the art. Summary of the invention
[0007] In view of the current needs, the inventors provide a novel type XX collagen. The type XX collagen herein has the effect of promoting cell adhesion and has a triple helix structure. The present invention also provides a method for biosynthesizing type XX collagen as a human structural material.
[0008] In one aspect, a collagen is provided, comprising one or more repeating units, wherein the repeating unit comprises:
[0009] (1) the amino acid sequence shown in SEQ ID NO:9; or
[0010] (2) an amino acid sequence in which one or more amino acid residues are mutated in the amino acid sequence shown in SEQ ID NO: 9; or
[0011] (3) an amino acid sequence that is at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 95%, at least 96% or at least 99% identical to the amino acid sequence of SEQ ID NO:9.
[0012] In one embodiment, the number of repeating units is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20; each repeating unit is directly linked by a peptide bond or by a linker of one or more amino acids.
[0013] In one embodiment, the mutation is a substitution, insertion, deletion or addition; preferably, the substitution is a conservative amino acid substitution.
[0014] In one embodiment, the collagen is of human origin.
[0015] In one embodiment, the collagen has cell adhesion function.
[0016] In one embodiment, the collagen is recombinant collagen, recombinant humanized collagen or recombinant humanized type XX collagen.
[0017] In one embodiment, the collagen is in a single chain form.
[0018] In one embodiment, the addition is (Gly-XY)m at the N-terminus and / or C-terminus of the repeat unit, wherein X and Y are any amino acid residues and m is 1-5.
[0019] In one embodiment, Gly-XY is GER, GEK, GEP or GTS.
[0020] In one embodiment, the repeat sequence comprises the following amino acid sequence:
[0021] (1) the amino acid sequence shown in SEQ ID NO: 1 or 8;
[0022] (2) an amino acid sequence that has at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1 or 8; or
[0023] (3) An amino acid sequence in which one or more amino acid residues in the amino acid sequence shown in SEQ ID NO: 1 or 8 are mutated; preferably, the mutation is a substitution, insertion, deletion or addition; preferably, the substitution is a conservative amino acid substitution.
[0024] In one embodiment, the collagen comprises any one of SEQ ID NO: 1, 2, 5-9, or an amino acid sequence that is at least 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 1, 2, 5-9.
[0025] In one aspect, a collagen is provided, comprising one or more repeating units, the repeating units comprising the amino acid sequence shown in SEQ ID NO: 1 or 8, or an amino acid sequence in which one or more amino acid residues are mutated in the amino acid sequence shown in SEQ ID NO: 1 or 8, or an amino acid sequence that is at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 95%, at least 96% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 1 or 8; the number of repeating units is 2-20, 3-16 or 4-8.
[0026] In one embodiment, the number of repeating units is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.
[0027] In one embodiment, each repeating unit is directly linked by a peptide bond or is linked by a linker of one amino acid or multiple amino acid residues. In one embodiment, the linker comprises 2, 3, 4, 5, 6, 7 or 8 amino acid residues.
[0028] In one embodiment, the mutation is a substitution, insertion, deletion or addition. In one embodiment, the substitution is a conservative amino acid substitution.
[0029] In one embodiment, the collagen is derived from humans. In one embodiment, the collagen has a triple helix structure. In one embodiment, the triple helix structure is formed by three identical single-stranded collagens. In one embodiment, the collagen has cell adhesion efficacy. In one embodiment, the collagen is recombinant collagen, recombinant humanized collagen, or recombinant humanized type XX collagen.
[0030] In one embodiment, the collagen comprises the following amino acid sequence:
[0031] (1) the amino acid sequence shown in SEQ ID NO: 2;
[0032] (2) an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 2; or
[0033] (3) An amino acid sequence in which one or more amino acid residues are mutated in the amino acid sequence shown in SEQ ID NO: 2.
[0034] In one embodiment, the mutation is a substitution, insertion, deletion or addition. In one embodiment, the substitution is a conservative amino acid substitution.
[0035] In one aspect, a fusion protein is provided, which comprises the collagen herein and a protein for promoting the secretion, separation and / or purification of collagen.
[0036] In one embodiment, the protein is selected from the group consisting of a restriction site sequence, a signal peptide, and a purification tag sequence.
[0037] In one embodiment, the cleavage site sequence is a TEV protease cleavage site sequence.
[0038] In one embodiment, the protein tag sequence is a His tag, a GST tag, an MBP tag, a SUMO tag, a Cytiva Protein Select tag, or a NusA tag.
[0039] In one embodiment, the collagen is linked to the protein directly or via a linker, which is a flexible linker such as (G) a or (GGGGS) b , wherein a and b are each independently an integer of 1-10 or 1-5 or 1-3.
[0040] In one aspect, a nucleic acid is provided that encodes a collagen or fusion protein as described herein.
[0041] In one embodiment, the nucleic acid has the nucleotide sequence shown in SEQ ID NO:3.
[0042] In one aspect, a vector is provided, comprising a nucleic acid according to the present invention. In one embodiment, the vector comprises nucleotides encoding a purification tag, nucleotides encoding a leader and / or a regulatory element.
[0043] In one embodiment, the purification tag is selected from a His tag, a GST tag, an MBP tag, a SUMO tag, a Cytiva Protein Select tag or a NusA tag.
[0044] In one embodiment, the regulatory element is selected from a promoter, a terminator and / or an enhancer.
[0045] In one aspect, a host cell is provided, comprising a nucleic acid described herein or a vector described herein.
[0046] In one embodiment, the host cell is a eukaryotic cell or a prokaryotic cell. In one embodiment, the eukaryotic cell is a yeast cell, an animal cell and / or an insect cell, and / or the prokaryotic cell is an E. coli cell, such as E. coli BL21.
[0047] In one aspect, a collagen having a triple helical structure is provided, which comprises three identical single-chain collagens according to claim 1 or 2.
[0048] In one aspect, a method for producing a collagen or fusion protein is provided, comprising:
[0049] (1) culturing the host cell described herein under appropriate culture conditions;
[0050] (2) harvesting host cells and / or culture medium containing the collagen or fusion protein; and
[0051] (3) Purification of collagen or fusion protein, for example, including (1) crude purification of collagen on a Ni affinity chromatography column; (2) enzymatic cleavage; and / or (3) purification of collagen on an ion exchange column.
[0052] In one aspect, a composition is provided, which comprises the collagen, nucleic acid, vector, collagen having a triple helical structure and / or host cell described herein.
[0053] In one embodiment, the composition is a pharmaceutical composition or a cosmetic composition.
[0054] In one embodiment, the composition is one or more of biological dressings, human bionic materials, plastic surgery materials, organoid culture materials, cardiovascular stent materials, coating materials, tissue injection filling materials, ophthalmic materials, obstetrics and gynecology biomaterials, nerve repair and regeneration materials, liver tissue materials and vascular repair and regeneration materials, 3D printed artificial organ biomaterials, cosmetic raw materials, pharmaceutical excipients and food additives.
[0055] In one embodiment, the composition comprises a pharmaceutically and / or cosmetically acceptable carrier.
[0056] In one embodiment, the composition is a solid, liquid or gel composition.
[0057] In one embodiment, the composition is an oral and / or topically administrable composition.
[0058] In one embodiment, the composition is a kit.
[0059] In one embodiment, the composition is a liquid formulation comprising the collagen or collagen having a triple helical structure as described herein and a pharmaceutically and / or cosmetically acceptable carrier.
[0060] In one embodiment, the carrier is a buffer, such as D-PBS buffer or PBS buffer.
[0061] In one aspect, a method of promoting cell adhesion or attachment is provided, the method comprising contacting the cells with the collagen and / or composition herein.
[0062] On the one hand, provided is the use of the collagen, nucleic acid, vector, host cell, collagen with a triple helix structure and / or composition described herein in one or more of biological dressings, human bionic materials, plastic surgery materials, organoid culture materials, cardiovascular stent materials, coating materials, tissue injection filling materials, ophthalmic materials, obstetrics and gynecology biomaterials, nerve repair and regeneration materials, liver tissue materials, vascular repair and regeneration materials, and 3D printed artificial organ biomaterials.
[0063] In one embodiment, the biological dressing is a collagen biological dressing.
[0064] In one aspect, provided is a use of the collagen, collagen having a triple helical structure and / or the composition described herein in the preparation of a drug or a kit for promoting cell adhesion or cell wall adhesion.
[0065] In another aspect, a method for forming collagen in the form of a triple helical structure is provided, which comprises the step of dissolving the collagen described herein in the form of a single chain in water or a buffer, such as a D-PBS buffer or a PBS buffer.
[0066] In another aspect, a method for screening collagen is provided, comprising: mutating one or more amino acid residues of the amino acid sequence of SEQ ID NO: 9 to obtain a collagen library;
[0067] The cell adhesion activity was measured for each collagen in the collagen library;
[0068] Select collagen with cell adhesion activity.
[0069] In one embodiment, the mutation is a substitution, insertion, deletion or addition.
[0070] In one embodiment, the substitutions are conservative amino acid substitutions.
[0071] In one embodiment, the substitution, insertion or deletion is of 1-6 amino acid residues.
[0072] In one embodiment the addition is of 1-15 amino acid residues.
[0073] In one embodiment, the linker is a linker of 2, 3, 4, 5, 6, 7 or 8 amino acid residues.
[0074] In one embodiment, the addition is (Gly-XY)m at the N-terminus and / or C-terminus of the repeating unit, wherein X and Y are any amino acid residues and m is 1-5.
[0075] In one embodiment, the Gly-XY is GER, GEK, GEP or GTS.
[0076] In one embodiment, the selected collagen comprises the amino acid sequence of SEQ ID NO: 1 or 8.
[0077] In one embodiment, the method further comprises repeating SEQ ID NO: 9 or a selected collagen as a repeating unit 2 or more times in series, for example 2-30 times.
[0078] In one embodiment, the method comprises measuring the cell adhesion activity of a collagen comprising 2 or more repeating units; and
[0079] Collagen containing 2 or more repeating units was selected to have cell adhesion activity.
[0080] In one embodiment, the number of repeating units of the selected collagen comprising 2 or more repeating units is 2-12.
[0081] The advantages of the present invention include: the collagen described herein is a new humanized type XX collagen, which has the effect of promoting cell adhesion and has a triple helix structure; the recombinant humanized collagen C20 herein has a higher (e.g., about 2 times) cell adhesion activity than bovine type I collagen, achieving unexpected technical effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0082] Figure 1 The electrophoresis diagram of C20 collagen (also referred to as recombinant humanized type XX collagen C20) is shown.
[0083] Figure 2 The cell adhesion effect of C20 collagen is shown.
[0084] Figure 3 The circular dichroism spectrum of C20 collagen is shown.
[0085] Figure 4 A graph showing the relative cell adhesion ratios of C1, C2, and C3 collagens.
[0086] Figure 5 The electropherograms of C20T6 and C20T9 are shown.
[0087] Figure 6 A graph showing the relative cell adhesion ratios of C20T6 and C20T9 is shown. DETAILED DESCRIPTION
[0088] In order to make the purpose, technical solutions and advantages of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0089] As used herein, recombinant humanized collagen is a full-length or partial amino acid sequence fragment encoded by a sex-specific gene of human collagen prepared by DNA recombinant technology, or a combination of functional fragments of human collagen. In this article, recombinant humanized collagen is recombinant humanized type XX collagen, which is a peptide or polypeptide of multiple amino acid residues connected by peptide bonds.
[0090] As used herein, "collagen" refers to a protein of multiple repeating units connected by peptide bonds. As used herein, with respect to collagen or a specific amino acid sequence, "C-terminus" and "N-terminus" refer to the position relative to the collagen or the specific amino acid sequence, specifically to the carboxyl terminal or amino terminal direction of the collagen or the specific amino acid sequence.
[0091] In this article, from N-terminus to C-terminus, collagen may include an N-terminal sequence and a C-terminal sequence. The N-terminal sequence may include one or more repeating units, and the repeating unit includes an amino acid sequence shown in SEQ ID NO.9, 1 or 8 or an amino acid sequence after mutation (substitution, addition, insertion or deletion) of one or more amino acid residues in the amino acid sequence. The number of repeating units may be 1-20. For example, the number of repeating units is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20. In particular, the mutation may be a substitution, such as a conservative amino acid substitution. The amino acid sequence of SEQ ID NO.1 is GTSGERGPPGTVGPTGLPGPKGERGEKGEP. When the collagen sequence is mutated or there is a spacer sequence, the resulting collagen retains the functions of the present invention, such as cell adhesion, the ability to form a gel by itself, etc.
[0092] Herein, collagen may be single-chain collagen or triple-helix collagen. Triple-helix collagen may be formed by or include three identical single-chain collagens.
[0093] As used herein, "repeating unit" refers to an amino acid sequence as a basic sequence in collagen. The collagen herein can be obtained by multiple tandem repetitions of the repeating unit. In this article, collagen can include a repeating unit or a tandem repetition of multiple repeating units. The repeating unit includes the amino acid sequence shown in SEQ ID NO:9 or the amino acid sequence after mutation (replacement, addition, insertion or deletion) of one or more amino acid residues of the amino acid sequence. The number of repeating units can be 1-30. For example, the number of repeating units is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30. In particular, the mutation can be a substitution, such as a conservative amino acid substitution. Those skilled in the art can obtain collagen that retains the functions of the collagen of the present invention, such as cell adhesion, the ability to form a gel by itself, etc., when the collagen sequence undergoes appropriate mutations or there is an appropriate spacer sequence.
[0094] As used herein, "fusion protein" refers to a fusion of a protein comprising collagen and another functional part. In some embodiments, the protein of the other functional part is a protein for promoting collagen secretion, separation and / or purification. Proteins for promoting collagen secretion, separation and / or purification are well known to those skilled in the art and include, but are not limited to, restriction site sequences, signal peptides and purification tag sequences. In some embodiments, the restriction site sequence is a TEV protease cleavage site sequence. In some embodiments, the protein tag sequence His tag, GST tag, MBP tag, SUMO tag, Cytiva Protein Select tag or NusA tag. Collagen and the protein may be directly connected or may be connected via a linker. The choice of the linker is routine for those skilled in the art, and the linker may typically be a flexible linker, such as (G) a or (GGGGS) b , wherein a and b are each independently an integer of 1-10 or 1-5 or 1-3.
[0095] As used herein, "nucleic acid" refers to a plurality of nucleotides linked by internucleotides. Internucleotide linkages may be, for example, phosphodiester bonds. The nucleic acid herein may comprise a polynucleotide encoding the collagen of the present invention. In order to facilitate subsequent processing of the collagen, the nucleic acid of the present invention may also comprise nucleotides encoding a purification tag, such as a His tag, a GST tag, an MBP tag, a SUMO tag, a Cytiva Protein Select tag tag, or a NusA tag, and a nucleotide sequence encoding a leader sequence when necessary.
[0096] As used herein, the term "vector" is a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection so that the genetic material elements it carries are expressed in the host cell. Vectors are well known to those skilled in the art, including but not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or artificial chromosomes (PAC) derived from P1; bacteriophages such as lambda phage or M13 phage and animal viruses, etc. The vector may contain a variety of elements for controlling expression, including but not limited to promoter sequences, transcription start sequences, enhancer sequences, selection elements and reporter genes. In addition, the vector may also contain a replication initiation site. The vector may contain a nucleic acid of the present invention to facilitate introduction into cells for expression. The vector may contain expression control elements such as promoters, terminators and / or enhancers that are operably linked to the nucleic acid.
[0097] As used herein, the term "host cell" is a cell into which a nucleic acid molecule has been introduced by molecular biology techniques. These techniques include transfection of viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration. The host cell can be a eukaryotic cell or a prokaryotic cell. For example, a eukaryotic cell is a yeast cell, an animal cell, and / or an insect cell. A prokaryotic cell can be an E. coli cell.
[0098] As used herein, the degree of association between two amino acid sequences or between two nucleotide sequences is described by parameter " sequence identity ".For purposes of the present invention, use as in EMBOSS software package (EMBOSS: European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. [Genetics Trend] 16: 276-277) (preferred 5.0.0 version or updated version) Niederman-Wunsch algorithm (Needleman and Wunsch, 1970, J.Mol.Biol. [J.Molecular Biology] 48: 443-453) determine the sequence identity between two amino acid sequences.The parameter used is gap opening penalty 10, gap extension penalty 0.5 and EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.The output (using non-simplified option to obtain) of Nieder marked as "longest identity" is used as identity percentage and is calculated as follows:
[0099] (number of identical residues x 100) / (length of alignment - total number of gaps in the alignment)
[0100] For the purposes of the present invention, the sequence identity between two deoxynucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra) implemented by the Needle program of the EMBOSS software package (EMBOSS: European Molecular Biology Open Software Suite, Rice et al., 2000, supra) (preferably 5.0.0 version or updated version). The parameters used are gap opening penalty 10, gap extension penalty 0.5, and EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. The output of Needle, labeled "longest identity", (obtained using the non-simplified option) is used as identity percentage and is calculated as follows:
[0101] (number of identical deoxyribonucleotides x 100) / (length of alignment - total number of gaps in alignment)
[0102] In the context of the present invention, conservative amino acid substitutions or conservative substitutions may be defined by substitutions within the amino acid classes reflected in one or more of the following tables:
[0103] Conservative categories of amino acid residues:
[0104] Acidic residue D and E Basic residues K, R, and H Hydrophilic uncharged residues S, T, N and Q Aliphatic uncharged residue G, A, V, L, and I Nonpolar uncharged residues C, M and P Aromatic residues F, Y and W
[0105] Physical and functional classification of candidate amino acid residues:
[0106] Alcohol residue S and T Aliphatic residues I, L, V, and M Cycloalkenyl related residues F, H, W, and Y Hydrophobic residues A, C, F, G, H, I, L, M, R, T, V, W and Y Negatively charged residues D and E Polar residues C, D, E, H, K, N, Q, R, S, and T Positively charged residues H, K and R Small residues A, C, D, G, N, P, S, T and V Minimal residue A, G, and S Residues involved in turn formation A, C, D, E, G, H, K, N, Q, R, S, P and T Flexible residues Q, T, K, S, G, P, D, E, and R
[0107] "Collagen biological dressing" is a membrane-like or sponge-like biological dressing formed by cross-linking collagen extracts through physical or chemical methods. It can be used to cover and seal skin wounds.
[0108] "Bionic materials" refer to materials developed by imitating various characteristics or properties of living things. Artificial materials designed and manufactured by imitating the operating mode of life systems and the structural laws of biological materials are usually called bionic materials. Human bionic materials are artificial materials designed and manufactured by imitating the operating mode of human life systems and the structural laws of biological materials. The collagen in this article has the effect of promoting cell adhesion, so it can be used in human bionic materials.
[0109] "Plastic surgery cosmetic material" refers to a material used in cosmetology. It is known to those skilled in the art that collagen can be applied to the human body in cosmetology.
[0110] "Organoid culture material" refers to a material used to culture organoids. The collagen herein has the effect of promoting cell adhesion, and thus can be used for organoid culture.
[0111] "Cardiovascular stent material" refers to the material used in the preparation of cardiovascular stents. The collagen herein can be coated on the surface of the cardiovascular stent.
[0112] "Materials for tissue injection and filling" refers to materials that can be used for injection into the human body and as filling materials. The collagen herein can be used as a material for tissue injection and filling.
[0113] Recombinant humanized type XX collagen
[0114] Herein, collagen may be recombinant humanized type XX collagen. Unless otherwise specified, collagen may include collagen in single-chain form and / or triple-helix form. The collagen herein is sometimes also referred to as C20 collagen.
[0115] The recombinant humanized XX type collagen of the present invention may have certain mutations. For example, the amino acid sequence of one or more of these parts may have substitution, deletion, addition or insertion of amino acid residues. That is, the present invention can use variants as long as the variants retain the activity of promoting cell adhesion and / or proliferation. Specifically, the variants may have a certain percentage identity with the specified sequence, such as at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity. The specified sequence can be any sequence of the present invention, such as SEQ ID NO: 1 or 2, but it is preferred that these variants retain the function of the recombinant humanized XX type collagen of the present invention. The recombinant humanized XX type collagen of the present invention may have good cell adhesion efficacy. The recombinant humanized XX type collagen of the present invention may have a triple helical structure (i.e., collagen in triple helical form).
[0116] The recombinant humanized type XX collagen of the present invention can be prepared by any suitable method, for example, it can be prepared by synthesis. Preferably, the recombinant humanized type XX collagen of the present invention can be prepared by recombinant means.
[0117] The collagen of the present invention may have a triple helical structure region, i.e., a collagen in the form of a triple helical structure, i.e., having three identical collagen chains. For example, the collagen has a flexible triple helical structure region. The collagen of the present invention may form a triple helical structure. After determination, the recombinant humanized type XX collagen (C20 collagen) of the present invention may form a triple helical structure.
[0118] Repeating Unit
[0119] Provided herein are multiple repeating units, wherein the smallest repeating unit comprises an amino acid sequence of SEQ ID NO:9 and a variant amino acid sequence of SEQ ID NO:9. In some embodiments, the variant amino acid sequence of SEQ ID NO:9 comprises an amino acid sequence having at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with the amino acid sequence of SEQ ID NO:9. In some embodiments, the variant amino acid sequence of SEQ ID NO:9 comprises an amino acid sequence of SEQ ID NO:9 after mutation of 1-15 amino acid residues. The mutation may be a substitution, insertion, deletion or addition. For example, one skilled in the art can replace, insert, delete or add one or more (e.g., 1-15, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15) amino acid residues in the amino acid sequence of SEQ ID NO: 9, while retaining the function of the original repeating unit. In some embodiments, one or more (e.g., 1-15, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15) amino acid residues can be added to the N-terminus and / or C-terminus of the amino acid sequence of SEQ ID NO: 9, while retaining the function of the original repeating unit. In some embodiments, the addition is the addition of the motif (Gly-XY) m at the N-terminus and / or C-terminus of the repeating unit, wherein X and Y are any amino acid residues and m is 1-5. In some embodiments, Gly-XY is GER, GEK, GEP or GTS.
[0120] Prior art Diane et al. (THE JOURNAL OF BIOLOGICAL C HEMISTRY vol.275, No.19, Issue of May 12, pp.14532-14536, 2000) proved that the tripeptide unit GER is usually present in the collagen sequence, can form a triple helix structure in the absence of a typical collagen-like tripeptide unit, and plays a role in the stability of the triple helix structure. In the present invention, by adding a Gly-XY sequence to the N-terminus and C-terminus of SEQ ID NO:1, SEQ ID NO:1 or SEQ ID NO:8 is obtained. The extended collagen obtained before the biological activity is assumed to also have cell adhesion activity. After verification by experiments in the embodiments, consistent with the initial assumption, the collagen of SEQ ID NO:1 or SEQID NO:8 does retain the cell adhesion function of SEQ ID NO:9.
[0121] In some embodiments, the repeat unit comprises the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 8, or an amino acid sequence having at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to the amino acid sequence of SEQ ID NO: 1 or 8. In some embodiments, the variant amino acid sequence of SEQ ID NO: 1 or 8 comprises the amino acid sequence of SEQ ID NO: 1 or 8 after mutation of 1-15 amino acid residues. The mutation can be a substitution, insertion, deletion or addition. For example, one skilled in the art can substitute, insert, delete or add one or more (e.g., 1-15, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15) amino acid residues in the amino acid sequence of SEQ ID NO: 1 or 8 while retaining the function of the original repeat unit.
[0122] Tandem duplication strategy of collagen repeating units
[0123] Prior art literature reports that recombinant collagen can be constructed by tandem repetition of repeating units. The number of repeating units may vary. For example, Chen Hua et al. Biochemical and Biophysical Research Communications 508 (2019) 1018e1023 disclosed that the GERGAPGFRGPAGPNGIPGEKGPAGERGAP repeating unit and 16 tandem repeats of T16 of the repeating unit all have cell adhesion activity, and it is believed that recombinant proteins containing multiple tandemly repeated triple helical fragments can have a more stable helical conformation or a more favorable ligand binding configuration to promote cell membrane attachment and adhesion.
[0124] R. Strawn et al., Biopolymers 109 (2018), e23226 demonstrated that recombinant collagen-like proteins with multiple identical triple-helical peptide units arranged in a tandem repeat manner can self-assemble into microfibers for use in biopharmaceuticals and industrial fields.
[0125] J. Yao et al., J. Biochem. 136 (2004) 643e649 reported that a recombinant collagen-like protein containing tandem repeats of type I collagen peptides showed high cell adhesion activity.
[0126] The applicant's previous applications also demonstrated that recombinant collagen composed of different numbers of collagen repeating units can have excellent cell adhesion activity. The number of tandem repeats of the repeating unit within 1-30 can have the same properties.
[0127] Therefore, when the inventors have proved that the collagen of SEQ ID NO:2 has cell adhesion activity, those skilled in the art should understand that new collagen is formed by repeating SEQ ID NO:1 or 8 in series in other numbers. The formed collagen retains the adhesion fragments of SEQ ID NO:1 or 8, such as GER or GEK, and the peptide segments forming the triple helix structure, and therefore can have similar cell adhesion activity. For example, the recombinant collagen of the present invention can contain 1 repeating unit of SEQ ID NO:1 or 8, or can contain more than 2 repeating units, such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20. Each recombinant unit can be connected in series through peptide bonds to form a recombinant collagen.
[0128] Fusion Protein
[0129] Also contemplated herein are fusion proteins comprising the collagen described herein and proteins for promoting collagen secretion, separation and / or purification. Those skilled in the art will appreciate that the addition of these proteins is to promote collagen secretion, separation and / or purification without affecting the function of the collagen itself. In some embodiments, proteins for promoting collagen secretion, separation and / or purification. In some embodiments, the protein is selected from a cleavage site sequence, a signal peptide, and a purification tag sequence. In some embodiments, the cleavage site sequence is a TEV protease cleavage site sequence. In some embodiments, the protein tag sequence is a His tag, a GST tag, an MBP tag, a SUMO tag, a Cytiva Protein Select tag, or a NusA tag. In some embodiments, the collagen is directly connected to the protein or connected via a linker, and the linker is a flexible linker, such as (G) a or (GGGGS) b , wherein a and b are each independently an integer of 1-10 or 1-5 or 1-3.
[0130] Composition
[0131] The recombinant humanized type XX collagen of the present invention can be prepared as a composition. The composition may include the recombinant humanized type XX collagen described herein, nucleic acid, vector and / or host cell. The composition may also include a pharmaceutically and / or cosmetically acceptable carrier or solvent. The composition may be a pharmaceutical composition or a cosmetic composition for the purpose of medicine and / or cosmetics. For example, the composition is a biological dressing (e.g., a collagen biological dressing), a human bionic material, a plastic surgery material, an organoid culture material, a cardiovascular stent material, a coating material, a tissue injection filling material, an ophthalmic material (materials for ophthalmology), a gynecological biomaterial (biomaterials for gynaecology), a nerve repair and regeneration material (materials for neurorestoration and neuroregeneration), a liver tissue material (materials for liver tissue engineering) and a vascular repair and regeneration material (materials for vascular repair and regeneration), a 3D printing artificial organ biomaterial (biomaterial for 3D printing of artificial organ), a cosmetic raw material, a pharmaceutical excipient and a food additive. One or more.
[0132] The cosmetic composition may be a cosmetic composition having anti-wrinkle effect, skin oil control effect, skin repair effect and / or skin soothing effect. The part to which the cosmetic composition is applied is not particularly limited, and may be the face, hands, legs, trunk, etc. For example, the skin oil control effect is the facial skin oil control effect.
[0133] The form of the composition is not particularly limited as long as the intended function can be achieved. For example, the composition is a solid, liquid or gel composition.
[0134] The composition can be used in any suitable manner, for example, for oral and / or topical compositions. The composition can also be prepared as a test kit. The test kit can include additional ingredients, for example auxiliary ingredients, such as buffers, and include instructions for use. In particular, the composition can be formulated into a suitable formulation, such as a liquid formulation. The formulation can include a buffer, such as a D-PBS buffer or a PBS buffer.
[0135] method
[0136] Provided herein is a method for making cells adhere or adhere to a wall, the method comprising contacting the cells with the recombinant humanized type XX collagen, composition and / or liquid formulation described herein. The method of the present invention can be performed in vitro to increase the adhesion of cells to a culture container. Alternatively, the method of the present invention can also be performed in vivo.
[0137] Also provided herein is a cosmetic method comprising administering to a subject the recombinant humanized type XX collagen, composition and / or liquid formulation described herein. The administration may be oral administration.
[0138] Screening methods
[0139] Provided herein is a method for screening collagen, comprising: mutating one or more amino acid residues of the amino acid sequence of SEQ ID NO: 9 to obtain a collagen library. Each collagen in the collagen library can be assayed for biological activity, such as cell adhesion activity. Collagen with cell adhesion activity can be selected based on the activity of the collagen (for example, compared with the parent collagen or bovine type I collagen). In one embodiment, the mutation is a substitution, insertion, deletion and / or addition. In one embodiment, the substitution is a conservative amino acid substitution. In one embodiment, the substitution, insertion or deletion is a substitution, insertion or deletion of 1-6 amino acid residues. In one embodiment, the addition is the addition of 1-15 amino acid residues. In one embodiment, the linker is a linker of 2, 3, 4, 5, 6, 7 or 8 amino acid residues. In one embodiment, the addition is the addition of (Gly-XY)m at the N-terminus and / or C-terminus of the repeating unit, wherein X and Y are any amino acid residues and m is 1-5. In one embodiment, Gly-XY is GER, GEK, GEP or GTS. In one embodiment, the selected collagen comprises the amino acid sequence of SEQ ID NO: 1 or 8. In one embodiment, the method further comprises tandemly repeating SEQ ID NO: 9 or the selected collagen as a repeating unit 2 or more times, for example, 2-30 and any integer therebetween. In one embodiment, the method further comprises determining the cell adhesion activity of the collagen comprising 2 or more repeating units; and selecting the collagen comprising 2 or more repeating units having cell adhesion activity. In one embodiment, the number of repeating units of the selected collagen comprising 2 or more repeating units is 2-12 and any integer therebetween.
[0140] Example
[0141] The following examples are provided to illustrate the present invention. Those skilled in the art should understand that the examples are merely illustrative and not limiting. The present invention is limited only by the scope of the appended claims.
[0142] Example 1-1: Construction, prokaryotic expression and screening of humanized type XX collagen fragments
[0143] 1. Perform large-scale functional region screening to obtain the following target gene functional regions of humanized type XX collagen.
[0144] Amino acid sequence of C20 collagen:
[0145] gtsgergppgtvgptglpgpkgergekgep
[0146] gtsgergppgtvgptglpgpkgergekgep
[0147] gtsgergppgtvgptglpgpkgergekgep
[0148] gtsgergppgtvgptglpgpkgergekgep (SEQ ID NO: 2).
[0149] The repeating unit of the amino acid sequence of C20 collagen is gtsgergppgtvgptglpgpkgergekgep (SEQ ID NO: 1).
[0150] The inventors designed the C20 collagen nucleotide sequence based on the amino acid sequence of C20 collagen.
[0151] Nucleotide sequence of C20 collagen:
[0152] GGATCCGAAAATCTGTATTTTCAGGGTACCAGCGGTGAACGTGGTCCG
[0153] CCGGGTACAGTTGGTCCTACAGGTTTACCGGGTCCTAAAGGTGAACGT
[0154] GGTGAAAAAGGTGAACCGGGTACCAGCGGTGAACGTGGTCCTCCTGG
[0155] TACAGTTGGTCCGACCGGTTTACCGGGTCCGAAAGGTGAACGTGGTGA
[0156] AAAAGGTGAACCGGGTACCAGCGGTGAACGTGGTCCTCCGGGTACAG
[0157] TTGGTCCGACAGGTTTACCTGGTCCGAAAGGTGAACGTGGTGAAAAAA
[0158] GGTGAACCGGGTACCAGCGGTGAACGTGGTCCTCCTGGTACAGTTGGT
[0159] CCGACAGGTTTACCGGGTCCGAAAGGTGAACGTGGTGAAAAAGGTGAACCGTAAAAGCTT (SEQ ID NO: 3).
[0160] 2. Construction of genetically engineered Escherichia coli
[0161] The nucleotide sequence of C20 collagen is cloned into an expression vector, and then the expression vector is transferred into an Escherichia coli expression strain, and the Escherichia coli genetic engineering bacteria are screened.
[0162] Specifically, according to the amino acid sequence of C20 collagen (SEQ ID NO: 2), the codon-optimized gene sequence SEQ ID NO: 3 preferred by Escherichia coli was optimized and selected. The nucleotide sequence of SEQ ID NO: 3 was synthesized. The nucleotide sequence of C20 collagen was inserted into the pET-32a expression vector (Beijing Liuhe Huada Gene Technology Co., Ltd.) through the restriction sites of Kpn I (NEB Company, Article No.: R0136L) and Xho I (NEB Company, Article No.: R0146L), and the pET-32a-C20 expression vector was constructed, and the expression vector was introduced into Escherichia coli BL21 (DE3), and the positive Escherichia coli genetic engineering bacteria were screened. The above operations were entrusted to Beijing Liuhe Huada Gene Technology Co., Ltd.
[0163] 3. Fermentation of genetically engineered Escherichia coli
[0164] The successfully constructed pET-32a-C20 expression vector was transformed into E. coli competent cells BL21 (DE3). The specific process is:
[0165] (1) Take out the E. coli competent cells BL21 (DE3) from the ultra-low temperature refrigerator and place them on ice. Take 2 μl of the expression plasmid to be transformed and add it to the competent cells BL21 (DE3). Mix gently 2-3 times.
[0166] (2) Place the mixture on ice for 30 min, then heat shock in a 42°C water bath for 45-90 s, remove from the heat and place on ice for 2 min.
[0167] (3) Transfer to a biosafety cabinet and add 700 μl of liquid LB medium, then culture at 37°C and 220 rpm for 60 min.
[0168] (4) Take 200 μl of bacterial solution and spread it evenly on LB plate containing ampicillin sodium.
[0169] (5) Incubate the plate in a 37°C incubator for 15-17 hours until colonies of uniform size grow.
[0170] (6) Pick 5-6 single colonies from the transformed LB plate and place them in a shake flask containing LB medium containing antibiotic stock solution, and incubate in a constant temperature shaker at 220 rpm and 37°C for 7 hours. Then cool the shake flask to 16°C, add IPTG to induce expression for a period of time, divide the bacterial solution into centrifuge bottles, centrifuge at 8000 rpm and 4°C for 10 minutes, collect the bacteria, record the bacterial weight, and take samples for electrophoresis detection.
[0171] (7) Resuspend the collected bacteria with a balanced working solution (200 mM sodium chloride, 25 mM Tris, 20 mM imidazole, pH 8.0), cool the bacterial solution to ≤15°C, homogenize, and homogenize twice under high pressure. Collect the bacterial solution after completion. Divide the homogenized bacterial solution into centrifuge bottles, centrifuge at 17,000 rpm and 4°C for 30 min, collect the supernatant, and take the supernatant and precipitate for electrophoresis detection.
[0172] (8). Purify and digest C20 collagen. The specific process is as follows: (1) Crude purification: a. Wash the column material (Ni6FF, Cytiva) with water for 5 CVs. b. Equilibrate the column material with equilibration solution (200mM sodium chloride, 25mM Tris, 20mM imidazole, pH8.0) for 5 CVs. c. Loading: Add the supernatant after centrifugation to the column material until the liquid flows out, and take the flow-through for electrophoresis. d. Wash the impurities: Add 25mL of washing solution (200mM sodium chloride, 25mM Tris, 20mM imidazole) until the liquid flows out, and take the washing flow-through for electrophoresis. e. Collect the target protein: Add 20mL of elution solution (200mM sodium chloride, 25mM Tris, 250mM imidazole, pH8.0), collect the flow-through, detect the protein concentration, calculate the protein amount, and perform electrophoresis. f. Wash the column with 1M imidazole working solution. g. Wash the column with purified water. (2) Enzyme digestion: Add TEV protease at a ratio of 50:1 between the total amount of protein and the total amount of TEV protease, digest at 16℃ for 4h, and take samples for electrophoresis detection. Put the protein solution after enzyme digestion into a dialysis bag, dialyze at 4℃ for 2h, and then transfer to new dialysis solution for overnight dialysis at 4℃. (3) Purification: a. Equilibrate the column: Use solution A (20mM Tris, 20mM sodium chloride, pH8.0) to equilibrate the column at a flow rate of 10ml / min. b. Loading: Load and collect the flow-through at a flow rate of 5ml / min, and perform electrophoresis detection. c. Gradient elution: Set 0-15% B solution (20mM Tris, 1M sodium chloride, pH8.0) for 2min and then keep for 3CVs, 15-30% B solution for 2min and then keep for 3CVs, 30-50% B solution for 2min and then keep for 3CVs, 50-100% B solution for 2min and then keep for 3CVs, collect the peaks and perform electrophoresis detection (for pure protein). d. Wash the column. Store the protein at 4°C.
[0173] Concentration detection: accurately measure an appropriate amount of sample, dilute it 10-50 times with the eluent, and stir it thoroughly with a glass rod. Use a UV-visible spectrophotometer to measure the absorbance at 280nm, and calculate the protein concentration according to the formula C (mg / ml) = A280 x absorbance coefficient x dilution factor (Note: the absorbance value must be between 0.1-1).
[0174] The specific process of electrophoresis detection is as follows: take 40 μl of sample solution, add 10 μl 5x protein loading buffer (250 mM Tris-HCl (pH: 6.8), 10% SDS, 0.5% bromophenol blue, 50% glycerol, 5% β-mercaptoethanol), place in 100°C boiling water for 10 min, then add 10 μl to each well into SDS-PAGE protein gel, run at 80 V for 2 h, use Coomassie Brilliant Blue staining solution (0.1% Coomassie Brilliant Blue R-250, 25% isopropanol, 10% glacial acetic acid) for protein staining for 20 min, and then use protein decolorizing solution (10% acetic acid, 5% ethanol) for decolorization.
[0175] The electrophoresis test results of C20 collagen pure protein showed Figure 1 .like Figure 1 As shown, the actual molecular weight of the C20 collagen of the present invention is 11 kDa, and the purity is relatively high. The actual molecular weight of the purified C20 collagen is consistent with the expected molecular weight, indicating that the C20 collagen is correctly expressed.
[0176] Prospective Example 1-2: Prokaryotic Expression of Collagen 1-3
[0177] The following collagens will also be constructed in the same manner as the construction, prokaryotic expression and screening of C20 collagen. The amino acid sequences of the above collagens 1-3 are submitted to a gene synthesis company to synthesize the corresponding polynucleotide sequences. Collagen 1-3 is synthesized and expressed as described above. The molecular weight of collagen 1-3 is verified by SDS-PAGE experiment and each protein is confirmed to be correctly expressed.
[0178] Collagen 1:
[0179] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0180] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0181] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0182] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0183] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0184] GTSGERGPPGTVGPTGLPGPKGERGEKGEP (SEQ ID NO: 5; number of repeats is 6), a TEV protease cleavage site ENLYFQ can be added to the front end of this sequence.
[0185] Collagen 2:
[0186] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0187] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0188] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0189] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0190] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0191] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0192] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0193] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0194] GTSGERGPPGTVGPTGLPGPKGERGEKGEP (SEQ ID NO: 6; number of repeats is 9), a TEV protease cleavage site ENLYFQ can be added to the front end of this sequence.
[0195] Collagen 3:
[0196] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0197] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0198] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0199] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0200] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0201] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0202] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0203] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0204] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0205] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0206] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0207] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0208] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0209] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0210] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0211] GTSGERGPPGTVGPTGLPGPKGERGEKGEP (SEQ ID NO: 7; number of repeats is 16), a TEV protease cleavage site ENLYFQ can be added to the front end of this sequence.
[0212] Collagen 4:
[0213] GERGPPGTVGPTGLPGPKGERGEK (SEQ ID NO: 8; number of repeats is 16), a TEV protease cleavage site ENLYFQ can be added to the front end of this sequence.
[0214] Example 2-1: Bioactivity Detection of C20 Collagen
[0215] The adhesion activity detection method of C20 collagen can refer to the literature Juming Yao, Satoshi Yanagisawa, Tetsuo Asakura, Design, Expression and Characterization of Collagen-Like Proteins Based on the Cell Adhesive and Crosslinking Sequences Derived from Native Collagens, J Biochem. 136, 643-649 (2004). The specific implementation method is as follows:
[0216] (1) The concentration of the protein sample to be tested is detected by ultraviolet absorption method, including bovine type I collagen (China Food and Drug Inspection Institute, No.: 380002) and C20 collagen provided by the present invention. Specifically, the ultraviolet absorption of the sample at 215nm and 225nm is measured respectively, and the protein concentration is calculated using the empirical formula C (μg / mL) = 144x (A215-A225). Note that the test must be performed when A215 < 1.5. The principle of this method is: to measure the characteristic absorption of peptide bonds under far-ultraviolet light, which is not affected by the chromophore content, has few interfering substances, is easy to operate, and is suitable for detecting human collagen and its analogs that are not colorable with Coomassie Brilliant Blue. (The reference is Walker JM. The Protein Protocols Handbook, second edition. Humana Press. 43-45). After the protein concentration is detected, the concentration of all proteins to be tested is adjusted to 0.5 mg / mL with PBS.
[0217] (2) Add 100 μL of various protein solutions (bovine type I collagen or C20 collagen) to a 96-well plate.
[0218] (3) Add 10 5 3T3 cells in good culture state were incubated at 37°C for 60 min.
[0219] (4) Wash each well four times with PBS.
[0220] (5) Use LDH detection kit (Roche, 04744926001) to detect the absorbance at OD492nm according to the manufacturer's instructions. The cell adhesion rate can be calculated based on the value of the blank control.
[0221] The formula for calculating the adhesion rate is as follows:
[0222]
[0223] The cell adhesion rate can reflect the adhesion activity of each protein. The higher the activity of the protein, the better the external environment it can provide to the cells in a short time, helping the cells to adhere to the wall.
[0224] The results are as follows Figure 2 As shown, it can be seen from the comparison that compared with bovine type I collagen (PC group, 0.5 mg / ml), the C20 collagen of the present invention has better bioadhesion activity. Figure 2 The relative cell adhesion activity of C20 collagen relative to bovine type I collagen is described, indicating that C20 collagen has higher (more than 2 times) cell adhesion activity than bovine type I collagen. It is unexpected that C20 collagen has such high cell adhesion activity.
[0225] Anticipated Example 2-2: Bioactivity Detection of Collagen 1-3
[0226] The biological activity of collagen 1-3 will be tested for adhesion activity in the same manner as in Example 2-1. According to prior art (e.g., Chen Hua et al., Biochemical and Biophysical Research Communications 508 (2019) 1018e1023; Li Yang et al., Biomaterials 276 (2021) 121055), recombinant collagen containing multiple tandemly repeated triple helical fragments can have a more stable helical conformation or a more favorable ligand binding configuration to promote cell membrane attachment and adhesion. The inventors expect that collagens 1-3 all have excellent cell adhesion activity. As described in subsequent Example 6, these collagens have been verified to have excellent cell adhesion activity.
[0227] Example 3: Circular dichroism spectrum of C20 collagen
[0228] 1) Sample preparation
[0229] Prepare phosphate buffer solution (PBS) 1X: dissolve 8g NaCl, 0.2g KCl, 3.62g Na2HPO4.12H2O and 0.24g KH2PO4 in 800ml distilled water, adjust the pH value of the solution to 7.4 with HCl, add water to make up to 1L, sterilize by high pressure, and store at room temperature. If the storage time is more than 1 week, filter through a 0.45 filter membrane if it is needed.
[0230] Sample dissolution: PBS was used to dissolve the freeze-dried flocculent sample. Each bottle contained 4 mg of C20 collagen. 2 mL of PBS was drawn into the vial with a syringe and injected into the vial (note the negative pressure in the vial. The syringe must accurately draw 2 mL of PBS). The final concentration was 2 mg / mL. Incubate at 4°C overnight.
[0231] Note: For protein samples, try to select samples with UV absorption value A lower than 2 for testing, and control HT (instrument voltage) between 170-700. When it is >700, the test result is not accurate enough. You can use reduced sample concentration, short wavelength cuvette, solvent replacement, etc. The recommended concentration is 1-0.5 mg / mL as the highest concentration, and it is recommended to set it according to the sensitivity of the instrument.
[0232] Sample testing:
[0233] Gradient dilution sample preparation: 1. Use an ice box ice maker to take ice, and dilute the overnight sample at 4°C twice (note to change the pipette tip), take 500 μl of the overnight sample, and the PBS dilution concentrations are 1.0, 0.5, 0.25, and 0.125 mg / mL respectively
[0234] 2) Instrument (JASCO circular dichroism spectrometer, JASCO J-815) parameter setting
[0235] Band width: 1.0nm
[0236] Step:1.0nm
[0237] Measurement range: 190-260nm
[0238] Time-per-point: 1s
[0239] Scanning speed: 50nm / min
[0240] Repeats: 3 times
[0241] Measurement temperature: 4°C
[0242] 3) Scanning of standard product CD
[0243] The scanning wavelength was set to 190-260 nm for blank buffer baseline test, and the circular dichroism absorption of the sample solution PBS in the range of 190-260 nm was collected.
[0244] 4) Scanning spectrum processing.
[0245] Figure 3 The circular dichroism spectrum of C20 collagen is shown. C20 collagen has a negative peak near 195 nm and a positive peak near 221 nm, and has a triple helical structure.
[0246] Prospective Example 4: Yeast Expression of Collagen 1
[0247] The inventors have commissioned a gene synthesis company to design a polynucleotide sequence suitable for expression in yeast (eg, Pichia pastoris) based on the amino acid sequences of collagen 1 and C20 collagen. A tag sequence of SEQ ID NO: 10 may be added to the N-terminus of the above collagen.
[0248] Collagen 1:
[0249] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0250] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0251] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0252] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0253] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0254] GTSGERGPPGTVGPTGLPGPKGERGEKGEP*(SEQ ID NO:5)
[0255] C20 Collagen
[0256] GTSGERGPPGTVGPTGLPGPKGERGEKGEPGTSGERGPPGTVGPTGL PGPKGERGEKGEPGTSGERGPPGTVGPTGLPGPKGERGEKGEPGTSGERG PPGTVGPTGLPGPKGERGEKGEP.
[0257] Cytiva Protein Select tag sequence: MVKIVSRKSLGVQNVYDIGVEKDHNFLLANGLIASN (SEQ ID NO: 10).
[0258] The cloning expression in yeast host cells can be found in Chinese patent application CN117126874A. The specific procedure is as follows: insert the commercially synthesized coding nucleotide sequence into the pPiczalαA expression vector to obtain recombinant expression plasmid 1 (expressing collagen 1) and expression plasmid 2 (expressing C20 collagen).
[0259] 1. Plasmid digestion
[0260] Take the successfully constructed expression plasmids 1 and 2, use sac1 for restriction digestion, and perform digestion at 37°C for 2-3 hours according to the restriction enzyme digestion ratio. After digestion, perform nucleic acid gel electrophoresis to detect the plasmid before and after digestion to verify whether all the digestion is complete and that the position of the band after digestion is greater than that before digestion.
[0261] 2. Plasmid Purification
[0262] The plasmid after enzyme digestion was purified using a plasmid purification kit to remove impurities such as ions, dissolved in 20-25ul sterilized purified water, tested for plasmid concentration, and placed at 4°C for later use.
[0263] 3. Yeast transformation
[0264] Take out the yeast competent cells (X33) and perform the following operations under a biosafety cabinet:
[0265] a. Take a 0.2 cm electric rotating cup, soak it in 75% alcohol for 10 minutes for disinfection, rinse it repeatedly with sterile water for 3 times and dry it;
[0266] b. Place the electroporator cup in an ice bath for 20 minutes and turn on the electroporator;
[0267] c. Add 80ul of competent cells and 5-15ug of digested plasmid into a sterilized 1.5ml EP tube and mix repeatedly using a pipette;
[0268] d. Transfer 100ul of the mixed solution to the electroporation cup. After ice bathing for 5 minutes, wipe the outer surface of the electroporation cup, transfer the electroporation cup to the electroporation instrument slot, click Start, and perform electroporation.
[0269] e. After the electroporation, add 1 ml of 1 M sterile sorbitol solution into the electroporation cup, seal it with sealing film, and incubate it at 30°C for 2 h.
[0270] f. Transfer the mixed solution in the electric rotating cup to a sterilized 10 ml EP tube, then add 1 ml of YPD liquid culture medium (0.2 g / L yeast peptone, 0.1 g / L yeast extract powder) into the EP tube and culture at 30°C, 300 rpm for 1 hour.
[0271] g. Plate spreading: Under a biosafety cabinet, take 200ul of the transformed and incubated bacterial solution and add it to the poured plates 1-3. Plate 4 is used as a control. Use a sterile coating rod to evenly spread the plates. After completion, culture the plates at 30℃ for about 2-5 days.
[0272] h. Culture of bacterial strains: Culture on a plate until plaques grow, add 10 ml of anhydrous glucose solution to 40 ml of YPD liquid medium, and wait until the temperature of the medium drops to room temperature; dispense 50 ml of the medium into 10 50 ml bioreactor tubes at 5 ml / tube, add bleomycin solution at a ratio of 2000 mg / L, pick 10 single clones on the plate and inoculate them into 10 small tubes for overnight culture at 30°C and 300 rpm; prepare 200 ml of BMGY medium, after sterilization, add 20 ml of 10*YNB stock solution and 200 ul of 500*biotin stock solution into a shaking flask and mix well; divide 200 ml of the medium into 10 50 ml centrifuge tubes, 20 ml / tube; then take 4 ml of the cultured bacterial solution and inoculate it into 10 centrifuge tubes of 20 ml / tube, and culture overnight until the OD value of the bacterial solution is between 3-10.
[0273] i. Induced expression: Prepare 500ml of BMMY culture medium. After sterilization, add 50ml10*YNB stock solution and 500ul 500*biotin stock solution to the shake flask and mix well. Divide 500ml of culture medium into 10 250ml shake flasks, 50ml / flask. Centrifuge the cultured bacterial solution at 1500rpm for 10min and discard the supernatant. Use the culture medium in 10 shake flasks to suspend the bacterial sediments in 10 centrifuge tubes and transfer them to their respective shake flasks for shake flask culture at 30℃ and 300rpm. Take 1ml of samples from 10 shake flasks every 24h and put them into 1.5ml EP tubes and store them at -20℃. Add 1% methanol (filtered with a 0.22um filter) to the shake flask to induce expression until the end of the 5th day. Centrifuge the sample in the 1.5ml EP tube at 12000rpm for 5min, take the supernatant for electrophoresis detection, and observe the expression of 10 clones respectively.
[0274] 4. Electrophoresis detection
[0275] The specific process is: take 40μl of sample solution, add 10μl 5× protein loading buffer (250mM Tris-HCl (pH: 6.8), 10% SDS, 0.5% bromophenol blue, 50% glycerol, 5% β-mercaptoethanol), place it in 100℃ boiling water for 10min, then add 10μl to each well of SDS-PAGE protein gel, run at 80V for 2h, use Coomassie Brilliant Blue staining solution (0.1% Coomassie Brilliant Blue R-250, 25% isopropanol, 10% glacial acetic acid) for protein staining for 20min, and then use protein decolorization solution (10% acetic acid, 5% ethanol) for decolorization.
[0276] The inventors will perform electrophoresis to detect the apparent molecular weight of the target protein. The inventors expect that collagen 1 and C20 collagen can be successfully expressed in yeast hosts.
[0277] 5. The inventors tested the biological activity and circular dichroism of collagen 1 and C20. The inventors expected that collagen 1 and C20 expressed by yeast cells have cell adhesion activity and triple helical structure.
[0278] Example 5: Screening and activity determination of humanized type XX collagen fragments
[0279] A large-scale functional region screening was conducted on the amino acid sequence of type XX collagen, and the following target gene functional regions C1-C3 of type XX collagen were obtained. The specific sequences are as follows. A peptide synthesis company was commissioned to synthesize C1-C3:
[0280] C1: GTSGERGPPGTVGPTGLPPGPKGERGEKGEP (SEQ ID NO: 1);
[0281] C2: GERGPPGTVGPTGLPGPKGERGEK (SEQ ID NO: 8);
[0282] C3: GPPGTVGPTGLPGPK (SEQ ID NO:9).
[0283] The adhesion activity of collagen C1-C3 was measured. The adhesion activity detection method can refer to the literature Juming Yao, Satoshi Yanagisawa, Tetsuo Asakura, Design, Expression and Characterization of Collagen-Like Proteins Based on the Cell Adhesive and Crosslinking Sequences Derived from Native Collagens, J Biochem. 136, 643-649 (2004). The specific implementation method is as follows:
[0284] (1) The concentration of the protein sample to be tested is detected by ultraviolet absorption method, including bovine type I collagen (China Food and Drug Inspection Institute, No.: 380002) and collagen C1-C3 provided by the present invention. Specifically, the ultraviolet absorption of the sample at 215nm and 225nm is measured respectively, and the protein concentration is calculated using the empirical formula C (μg / mL) = 144x (A215-A225). Note that the detection must be performed when A215 < 1.5. The principle of this method is: to measure the characteristic absorption of peptide bonds under far-ultraviolet light, which is not affected by the chromophore content, has few interfering substances, is easy to operate, and is suitable for detecting human collagen and its analogs that do not develop color with Coomassie Brilliant Blue. (The reference is Walker JM. The Protein Protocols Handbook, second edition. Humana Press. 43-45). After the protein concentration is detected, the concentration of all proteins to be tested is adjusted to 0.5 mg / mL with PBS.
[0285] (2) Add 100 μL of various protein solutions (bovine type I collagen or collagen C1-C3) to a 96-well plate.
[0286] (3) Add 10 5 3T3 cells in good culture state were incubated at 37℃ for 60min.
[0287] (4) Wash each well four times with PBS.
[0288] (5) Use LDH detection kit (Roche, 04744926001) to detect the absorbance at OD492nm according to the manufacturer's instructions. The cell adhesion rate can be calculated based on the value of the blank control.
[0289] The formula for calculating the adhesion rate is as follows:
[0290]
[0291] The cell adhesion rate can reflect the adhesion activity of each protein. The higher the activity of the protein, the better the external environment it can provide to the cells in a short time, helping the cells to adhere to the wall. Figure 1 It can be seen from the comparison that compared with bovine type I collagen (PC group, 0.5 mg / ml), the collagen C1-C3 of the present invention have better bioadhesion activity.
[0292] Chen Hua et al. Biochemical and Biophysical Research Communications 508 (2019) 1018e1023 disclosed that the GERGAPGFRGPAGPNGIPGEKGPAGERGAP repeating unit and 16 tandem repeats of the repeating unit T16 all have cell adhesion activity, and it is believed that recombinant proteins containing multiple tandem repeats of triple helical fragments can have a more stable helical conformation or a more favorable ligand binding configuration to promote cell membrane attachment and adhesion. The following is for C1 collagen GTSGERGPPGTVGPTGLPGPKGERGEKGEP (SEQ ID NO: 3). According to the teachings of the prior art, the sequence is repeated multiple times to determine whether the recombinant collagen with multiple repeats of SEQ ID NO: 3 also has cell adhesion activity.
[0293] Example 6: Prokaryotic expression and activity determination of recombinant collagen
[0294] 1. Design of recombinant collagen
[0295] The C1 collagen GTSGERGPPGTVGPTGLPGPKGERGEKGEP (SEQ ID NO: 1) obtained by screening in Example 1 was repeated 6 times to obtain collagen T6, and repeated 9 times to obtain collagen T9.
[0296] Collagen T6:
[0297] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0298] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0299] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0300] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0301] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0302] GTSGERGPPGTVGPTGLPGPKGERGEKGEP (SEQ ID NO: 5; repeat number is 6).
[0303] Collagen T9:
[0304] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0305] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0306] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0307] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0308] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0309] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0310] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0311] GTSGERGPPGTVGPTGLPGPKGERGEKGEP
[0312] GTSGERGPPGTVGPTGLPGPKGERGEKGEP (SEQ ID NO: 6; repeat number is 9).
[0313] 2. Construction of genetically engineered Escherichia coli
[0314] The nucleotide sequence of T6 or T9 collagen is cloned into an expression vector, and then the expression vector is transferred into an Escherichia coli expression strain, and the Escherichia coli genetic engineering bacteria are screened to obtain.
[0315] Specifically, according to the amino acid sequence of T6 and T9 collagen (TEV protease cleavage site ENLYFQ can be added to the front end of the sequence, SEQ ID NO: 4), the codon-optimized gene sequence preferred by Escherichia coli is optimized and selected. The polynucleotide sequence of T6 or T9 collagen is synthesized. The polynucleotide sequence of T6 or T9 collagen is inserted into the pET-32a expression vector (Beijing Liuhe Huada Gene Technology Co., Ltd.) through the restriction sites of Kpn I (NEB Company No.: R0136L) and Xho I (NEB Company, No.: R0146L), and the pET-32a-T6 or pET-32a-T9 expression vector is constructed, and the expression vector is introduced into Escherichia coli BL21 (DE3) respectively, and the positive Escherichia coli genetic engineering bacteria are screened. The above operations are entrusted to Beijing Liuhe Huada Gene Technology Co., Ltd.
[0316] 3. Fermentation of genetically engineered Escherichia coli
[0317] The successfully constructed pET-32a-T6 or pET-32a-T9 expression vector was transformed into E. coli competent cells BL21 (DE3). The specific process is:
[0318] (1) Take out the E. coli competent cells BL21 (DE3) from the ultra-low temperature refrigerator and place them on ice. Take 2 μl of the expression plasmid to be transformed and add it to the competent cells BL21 (DE3). Mix gently 2-3 times.
[0319] (2) Place the mixture on ice for 30 min, then heat shock in a 42°C water bath for 45-90 s, remove from the heat and place on ice for 2 min.
[0320] (3) Transfer to a biosafety cabinet and add 700 μl of liquid LB medium, then culture at 37°C and 220 rpm for 60 min.
[0321] (4) Take 200 μl of bacterial solution and spread it evenly on LB plate containing ampicillin sodium.
[0322] (5) Incubate the plate in a 37°C incubator for 15-17 hours until colonies of uniform size grow.
[0323] (6) Pick 5-6 single colonies from the transformed LB plate and place them in a shake flask containing LB medium containing antibiotic stock solution, and incubate in a constant temperature shaker at 220 rpm and 37°C for 7 hours. Then cool the shake flask to 16°C, add IPTG to induce expression for a period of time, divide the bacterial solution into centrifuge bottles, centrifuge at 8000 rpm and 4°C for 10 minutes, collect the bacteria, record the bacterial weight, and take samples for electrophoresis detection.
[0324] (7) Resuspend the collected bacteria with a balanced working solution (200 mM sodium chloride, 25 mM Tris, 20 mM imidazole, pH 8.0), cool the bacterial solution to ≤15°C, homogenize, and homogenize twice under high pressure. Collect the bacterial solution after completion. Divide the homogenized bacterial solution into centrifuge bottles, centrifuge at 17,000 rpm and 4°C for 30 min, collect the supernatant, and take the supernatant and precipitate for electrophoresis detection.
[0325] (8). Purify and digest collagen. The specific process is as follows: (1) Crude purification: a. Wash the column material (Ni6FF, Cytiva) with water for 5 column volumes (CV). b. Equilibrate the column material with equilibration solution (200mM sodium chloride, 25mM Tris, 20mM imidazole, pH8.0) for 5 CV. c. Loading: Add the supernatant after centrifugation to the column material until the liquid flows out, and take the flow-through for electrophoresis. d. Wash the impurities: Add 25mL of washing solution (200mM sodium chloride, 25mM Tris, 20mM imidazole) until the liquid flows out, and take the washing flow-through for electrophoresis. e. Collect the target protein: Add 20mL of elution solution (200mM sodium chloride, 25mM Tris, 250mM imidazole, pH8.0), collect the flow-through, detect the protein concentration, calculate the protein amount, and perform electrophoresis detection. f. Wash the column with 1M imidazole working solution. g. Wash the column with purified water. (2) Enzyme digestion: Add TEV protease at a ratio of 50:1 between the total amount of protein and the total amount of TEV protease, digest at 16℃ for 4h, and take samples for electrophoresis detection. Put the protein solution after enzyme digestion into a dialysis bag, dialyze at 4℃ for 2h, and then transfer to new dialysis solution for overnight dialysis at 4℃. (3) Purification: a. Equilibrate the column: Use solution A (20mM Tris, 20mM sodium chloride, pH8.0) to equilibrate the column at a flow rate of 10ml / min. b. Loading: Load and collect the flow-through at a flow rate of 5ml / min, and perform electrophoresis detection. c. Gradient elution: Set 0-15% B solution (20mM Tris, 1M sodium chloride, pH8.0) for 2min and then keep for 3CVs, 15-30% B solution for 2min and then keep for 3CVs, 30-50% B solution for 2min and then keep for 3CVs, 50-100% B solution for 2min and then keep for 3CVs, collect the peaks and perform electrophoresis detection (for pure protein). d. Wash the column. Store the protein at 4°C.
[0326] Concentration detection: accurately measure an appropriate amount of sample, dilute it 10-50 times with the eluent, and stir it thoroughly with a glass rod. Use a UV-visible spectrophotometer to measure the absorbance at 280nm, and calculate the protein concentration according to the formula C (mg / ml) = A280 x absorbance coefficient x dilution factor (Note: the absorbance value must be between 0.1-1).
[0327] The specific process of electrophoresis detection is as follows: take 40 μl of sample solution, add 10 μl 5x protein loading buffer (250 mM Tris-HCl (pH: 6.8), 10% SDS, 0.5% bromophenol blue, 50% glycerol, 5% β-mercaptoethanol), place in 100°C boiling water for 10 min, then add 10 μl to each well into SDS-PAGE protein gel, run at 80 V for 2 h, use Coomassie Brilliant Blue staining solution (0.1% Coomassie Brilliant Blue R-250, 25% isopropanol, 10% glacial acetic acid) for protein staining for 20 min, and then use protein decolorizing solution (10% acetic acid, 5% ethanol) for decolorization.
[0328] The electrophoresis results of T6 or T9 collagen purified protein were shown in Figure 5 .like Figure 5 As shown, the actual molecular weight of T6 or T9 is consistent with the expected molecular weight, and both are expressed correctly.
[0329] Example 7: Detection of biological activity of T6 or T9 collagen
[0330] As described in Example 2-1, the biological activity of T6 or T9 collagen was tested. Figure 6 As shown, it can be seen from the comparison that compared with bovine type I collagen (PC group, 0.5 mg / ml), the T6 or T9 collagen of the present invention has better bioadhesion activity. Figure 6 The relative cell adhesion activity of T6 or T9 collagen relative to bovine type I collagen is described, indicating that T6 or T9 collagen has higher cell adhesion activity than bovine type I collagen, which is unexpected.
[0331] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. Collagen comprising one or more repeating units, wherein the repeating units comprise: (1) the amino acid sequence shown in SEQ ID NO:9; or (2) an amino acid sequence in which one or more amino acid residues are mutated in the amino acid sequence shown in SEQ ID NO: 9; or (3) an amino acid sequence that is at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 95%, at least 96%, or at least 99% identical to the amino acid sequence of SEQ ID NO:9; The number of repeating units is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20; each repeating unit is directly connected by a peptide bond or connected by a linker of one or more amino acids; Preferably, the mutation is a substitution, insertion, deletion or addition; preferably, the substitution is a conservative amino acid substitution; Preferably, the collagen is derived from humans; Preferably, the collagen has cell adhesion effect; Preferably, the collagen is recombinant collagen, recombinant humanized collagen or recombinant humanized type XX collagen; Preferably, the collagen is in the form of a single chain.
2. The collagen according to claim 1, wherein the addition is the addition of (Gly-XY)m at the N-terminus and / or C-terminus of the repeating unit, wherein X and Y are any amino acid residues and m is 1-5; Preferably, the Gly-XY is GER, GEK, GEP or GTS; Preferably, the repetitive sequence comprises the following amino acid sequence: (1) the amino acid sequence shown in SEQ ID NO: 1 or 8; (2) an amino acid sequence that has at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1 or 8; or (3) an amino acid sequence in which one or more amino acid residues are mutated in the amino acid sequence shown in SEQ ID NO: 1 or 8; preferably, the mutation is a substitution, insertion, deletion or addition; preferably, the substitution is a conservative amino acid substitution; Preferably, the collagen comprises any one of SEQ ID NO: 1, 2, 5-9 or an amino acid sequence that is at least 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 1, 2, 5-9.
3. A fusion protein comprising the collagen according to claim 1 or 2 and a protein for promoting collagen secretion, separation and / or purification; Preferably, the protein is selected from a restriction site sequence, a signal peptide and a purification tag sequence; Preferably, the cleavage site sequence is a TEV protease cleavage site sequence; Preferably, the protein tag sequence is a His tag, a GST tag, an MBP tag, a SUMO tag, a Cytiva Protein Select tag or a NusA tag; Preferably, the collagen is directly linked to the protein or is linked via a linker, wherein the linker is a flexible linker, such as (G) a or (GGGGS) b , wherein a and b are each independently an integer of 1-10 or 1-5 or 1-3.
4. A nucleic acid encoding the collagen according to claim 1 or 2 or the fusion protein according to claim 3; preferably, wherein the nucleic acid comprises the nucleotide sequence shown in SEQ ID NO:
3.
5. A vector comprising the nucleic acid according to claim 4, optionally comprising nucleotides encoding a purification tag, nucleotides encoding a leader and / or a regulatory element; Preferably, the purification tag is selected from a His tag, a GST tag, an MBP tag, a SUMO tag or a NusA tag, a Cytiva Protein Select tag; Preferably, the regulatory element is selected from a promoter, a terminator and / or an enhancer.
6. A host cell comprising a nucleic acid according to claim 4 or a vector according to claim 5; wherein preferably, the host cell is a eukaryotic cell or a prokaryotic cell; wherein preferably, the eukaryotic cell is a yeast cell, an animal cell and / or an insect cell, and / or the prokaryotic cell is an Escherichia coli cell, such as Escherichia coli BL21; preferably, the yeast cell is Saccharomyces cerevisiae or Pichia pastoris, such as Pichia pastoris.
7. A method for producing collagen, wherein include: (1) culturing the host cell according to claim 6 under suitable culture conditions; (2) harvesting host cells and / or culture medium containing collagen; and (3) Purification of collagen or fusion protein, for example, including (1) crude purification of collagen on a Ni affinity chromatography column; (2) enzymatic cleavage; and / or (3) purification of collagen on an ion exchange column.
8. Collagen having a triple helix structure, comprising three identical single-chain collagens according to claim 1 or 2.
9. A composition comprising the collagen according to claim 1 or 2, the fusion protein according to claim 3, the nucleic acid according to claim 4, the vector according to claim 5, the host cell according to claim 6 and / or the collagen having a triple helical structure according to claim 8; Preferably, the composition is a pharmaceutical composition, a food composition or a cosmetic composition, Preferably, the composition is one or more of biological dressings, human bionic materials, plastic surgery materials, organoid culture materials, cardiovascular stent materials, coating materials, tissue injection filling materials, ophthalmic materials, obstetrics and gynecology biomaterials, nerve repair and regeneration materials, liver tissue materials and vascular repair and regeneration materials, 3D printing artificial organ biomaterials, cosmetic raw materials, pharmaceutical excipients and food additives; Preferably, the biological dressing is a collagen biological dressing; Preferably, the composition comprises a pharmaceutically and / or cosmetically acceptable carrier; Preferably, the composition is a solid, liquid or gel composition; Preferably, the composition is an oral and / or topical composition; Preferably, the composition is a kit; Preferably, the composition is a liquid formulation, which comprises the collagen according to claim 1 or 2 and a pharmaceutically and / or cosmetically acceptable carrier; preferably, the carrier is a buffer, such as D-PBS buffer or PBS buffer.
10. A method for promoting cell adhesion or cell attachment, the method comprising contacting cells with the collagen according to claim 1 or 2, the collagen having a triple helix structure according to claim 8, and / or the composition according to claim 9.
11. Use of the collagen according to claim 1 or 2, the fusion protein according to claim 3, the nucleic acid according to claim 4, the vector according to claim 5, the host cell according to claim 6, the collagen with a triple helix structure according to claim 8 and / or the composition according to claim 8 in one or more of biological dressings, human bionic materials, plastic surgery materials, organoid culture materials, cardiovascular stent materials, coating materials, tissue injection filling materials, ophthalmic materials, obstetrics and gynecology biomaterials, nerve repair and regeneration materials, liver tissue materials and vascular repair and regeneration materials and 3D printed artificial organs.
12. Use of the collagen according to claim 1 or 2, the fusion protein according to claim 3, the collagen with a triple helix structure according to claim 8 and / or the composition according to claim 9 in the preparation of a drug or kit for promoting cell adhesion or cell wall adhesion.
13. A method for forming collagen in the form of a triple helical structure, comprising the step of dissolving the collagen in the form of a single chain according to claim 1 or 2 in water or a buffer, such as a D-PBS buffer or a PBS buffer.
14. A cosmetic method, comprising administering the collagen according to claim 1 or 2, the collagen having a triple helix structure according to claim 8 and / or the composition according to claim 9 to a subject; preferably, the administration is oral administration.
15. A method for screening collagen, wherein include: mutating one or more amino acid residues of the amino acid sequence of SEQ ID NO: 9 to obtain a collagen library; The cell adhesion activity was measured for each collagen in the collagen library; Select collagen with cell adhesion activity; Preferably, the mutation is a substitution, insertion, deletion or addition; Preferably, the substitutions are conservative amino acid substitutions; Preferably, the substitution, insertion or deletion is a substitution, insertion or deletion of 1 to 6 amino acid residues; Preferably, the addition is of 1-15 amino acid residues; Preferably, the linker is a linker of 2, 3, 4, 5, 6, 7 or 8 amino acid residues; Preferably, the addition is the addition of (Gly-XY)m to the N-terminus and / or C-terminus of the repeating unit, wherein X and Y are any amino acid residues and m is 1-5; Preferably, the Gly-XY is GER, GEK, GEP or GTS; Preferably, the selected collagen comprises the amino acid sequence of SEQ ID NO: 1 or 8; Preferably, the method further comprises repeating SEQ ID NO: 9 or the selected collagen as a repeating unit 2 or more times in series, for example 2-30; Assaying cell adhesion activity for collagens comprising 2 or more repeating units; and Select collagen containing 2 or more repeating units with cell adhesion activity; Preferably, the number of repeating units of the selected collagen comprising 2 or more repeating units is 2-12.
Citation Information
Patent Citations
Method for biosynthesizing human body structural material type VI collagen
CN116948014A
Recombinant III type collagen Pro.C3 as well as preparation method and application thereof
CN117304306A
Recombinant human type xvii collagen, and preparation method and use thereof
US20230119018A1
Cited By
Recombinant VIII type humanized collagen and application thereof
CN120192400A
Recombinant I-type collagen with thermostable triple-helix structure and application of recombinant I-type collagen
CN120699135A
Human body structural material type xx collagen and biosynthesis method therefor
WO2025227927A1
